Tarsus Pharmaceuticals, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $TARS in the last 30 days.
See all $TARS insider activity →Tarsus Pharmaceuticals (TARS) former officer Aziz A. Mottiwala plans to sell up to 81,332 shares, valued at $5.84M, under Rule 144. He previously sold 53,043 shares in the past three months for $3.84M. The company has 43.88M shares outstanding.
Tarsus Pharmaceuticals (TARS) received a notice from former officer Aziz A. Mottiwala, who plans to sell 53,043 shares via Fidelity Brokerage Services. The shares, valued at $3.82M, are set to be issued from a stock option exercise on 08/19/2026. Tarsus has 43.88M shares outstanding.
Tarsus Pharmaceuticals (TARS) reported Q2 2026 XDEMVY net product sales of $173.9M, up 69% year over year, and raised full-year 2026 guidance to $685M to $705M. It agreed to acquire Alkeus Pharmaceuticals for $450M upfront and updated R&D guidance to $190M to $210M. Cash was $449.7M at June 30, 2026.
Over the past 7 days, alphai's AI scored 1 news story mentioning TARS (Tarsus Pharmaceuticals, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent TARS coverage spans mergers & acquisitions, financial news and earnings.
Potential short-term dilution and downward pressure on TARS price.
Potential modest increase in share supply could exert slight downward pressure on TARS price.
Near-term trading focus is on raised revenue guidance, the $450M Alkeus deal structure, and updated R&D spend that shifts the path to profitability into 2027.
Deal terms and milestone structure create a clear catalyst for TARS risk-reward, tied to regulatory and commercial milestones for gildeuretinol.
The acquisition adds a late-stage asset and creates a near-term catalyst for TARS around deal terms, regulatory path, and milestone probability.
alphai scores every news story that mentions TARS with an AI model for sentiment and relevance, and aggregates insider trades from Tarsus Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tarsus Pharmaceuticals (TARS) former officer Aziz A. Mottiwala plans to sell up to 81,332 shares, valued at $5.84M, under Rule 144. He previously sold 53,043 shares in the past three months for $3.84M. The company has 43.88M shares outstanding.
2 min readTarsus Pharmaceuticals (TARS) received a notice from former officer Aziz A. Mottiwala, who plans to sell 53,043 shares via Fidelity Brokerage Services. The shares, valued at $3.82M, are set to be issued from a stock option exercise on 08/19/2026. Tarsus has 43.88M shares outstanding.
1 min readTarsus Pharmaceuticals (TARS) reported Q2 2026 XDEMVY net product sales of $173.9M, up 69% year over year, and raised full-year 2026 guidance to $685M to $705M. It agreed to acquire Alkeus Pharmaceuticals for $450M upfront and updated R&D guidance to $190M to $210M. Cash was $449.7M at June 30, 2026.
6 min readTarsus will acquire privately held Alkeus Pharmaceuticals for up to $800m to advance gildeuretinol acetate (ALK-001), an investigational once-daily Phase III oral therapy for Stargardt disease. Tarsus will pay $450m upfront ($270m cash, $180m stock) plus up to $350m in milestone payments. Closing is expected later in 2026 pending regulatory approval.
5 min readMacquarie said global biotech funding for the year through Aug. 7 rose 75% YoY, driven by IPOs up 235% and follow-ons up 138%. The XBI biotech index gained 7% in the week to Aug. 7. Braveheart Bio’s upsized IPO raised $382.5M and shares jumped 66%. Curium agreed to buy Lantheus for up to $8B, and Supernus and Indivior plan an all-stock merger.
6 min readTarsus Pharmaceuticals (TARS) reported Q2 revenue of $173.91M and a net loss of $18.55M. The company raised 2026 XDEMVY net product sales guidance to $685M to $705M, citing strong uptake with 700,000+ patients treated. Tarsus also agreed to acquire Alkeus Pharmaceuticals to expand its ophthalmology pipeline.
4 min readTarsus Pharmaceuticals shares fell 0.8% to $64.79 after Q2 results. The company reported Q2 net product sales of $173.9m from XDEMVY, with a $18.6m net loss. Over the past year revenue was $606.3m, and management raised 2026 XDEMVY sales guidance to $685m-$705m. Cash and securities totaled $449.7m.
6 min readTarsus Pharmaceuticals (NASDAQ:TARS) reported Q2 call updates on XDEMVY adoption, saying daily prescribing by eye-care professionals doubled over the past year and retreatment rates are in the high teens, with stabilization near 20%. It also discussed ALK-001 for Stargardt disease, including Phase III NORTHSTAR enrollment and Phase II lesion reduction of ~29% vs placebo. Tarsus agreed to pay $450M upfront for Alkeus plus up to $350M milestones, and raised 2026 R&D guidance to $190M-$210M.
6 min readBiotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.
7 min readTarsus Pharmaceuticals agreed to acquire Alkeus Pharmaceuticals for about $450 million, consisting of $270 million cash and $180 million in Tarsus common stock priced at $61.38 per share. Alkeus holders may receive up to $350 million in milestones and tiered royalties on gildeuretinol. Deal approval is in place, with expected close in 2026.
5 min read
